Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic Tumor

NCT02330497 | Completed

• 1 other identifier: RFAP
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Advances in conventional imaging (abdominal ultrasound, CT scan, MRI) are so great that chance to discover a incidental solid or cystic pancreatic lesion is becoming usual. Endocrine tumors have variable malignant potential depending on their size, some malignancy for lesions larger than 2 cm and indefinite for a smaller size. The branch-duct like IPMN (intraductal papillary mucinous pancreatic tumor) involving the pancreatic secondary ducts represent half of pancreatic cystic tumors and may degenerate into 5 to 10% of cases. Signs and risk of degeneration are the presence of mural nodules greater than 5 mm and size \> 3 cm, although the latter criterion is discussed. Mucinous cystadenomas could degenerate between 30 and 50% of cases even though the role of size is much discussed (\<4 cm). The follow-up imaging is performed using MRI and endoscopic ultrasonography (EUS). A fine needle aspiration for cytology and histology is possible and determination of biological markers is useful. But cytology is often unprofitable due to the poor cellular profile of the cystic pancreatic tumor. Once the diagnosis of suspected malignancy, the patient should be referred to the surgeon for pancreatic resection more or less extensive. But this attitude is facing a significant operative risk with up to 30% of morbidity and mortality between 1 and 3 % for cephalic resections. Some patients with high post operative risks are inoperable. For these reasons, some teams have proposed the destruction of the walls of the cyst under EUS, US or CT control by washing with absolute alcohol content of cystic tumor. An interesting alternative endoscopic destruction would be the use of radio frequency ablation technique (RFA). RFA is a recognized technique for local tumor destruction by delivering thermal energy to obtain coagulation necrosis of the lesion. Taewong Medical ™ recently developed a radiofrequency needle EUSRA® coupled with a combo VIVA ™ generator for applying RFA sub EUS control. But no prospective study is available at this date regarding the treatment of the cystic or solid tumoral pancreatic lesion with this technique. The primary endpoint of the present study is to investigate the feasibility and safety of this guided radiofrequency probe EUS for the treatment of pancreatic endocrine tumors or inoperable pancreatic cystic tumors. The secondary objective will be the efficiency.

Conditions

Pancreatic Tumor; Endocrine Tumor; Neoplasms, Cystic, Mucinous, and Serous

Outcome Measures

Primary Outcomes (1)

• Safety of the pancreatic radiofrequency ablation under EUS guidance

  using the Cotton Classification

  At 3 months

Secondary Outcomes (2)

• Efficiency of the pancreatic radiofrequency ablation under EUS guidance

  At month 6 and 12

• Safety of the pancreatic radiofrequency ablation under EUS guidance

  At 7 days, one month, 6 and 12 months

Study Arms (1)

Radiofrequency

EXPERIMENTAL

Procedure/Surgery Thermal Radiofrequency Ablation under endoscopic ultrasonography guidance of the pancreatic neuro endocrine tumor or mucinous cyst.

Procedure: Radiofrequency Ablation under EUS

Interventions

Radiofrequency Ablation under EUS PROCEDURE

Pancreatic radiofrequency ablation under endoscopic ultrasonography guidance Procedure under general anesthesia Punction of the pancreatic lesion and aspiration of the liquid if present / then thermal ablation with a 18G needle (50 W during 10 secondes) - only one session

Also known as: Radiofrequency

Radiofrequency

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Pancreatic neuro endocrine tumor \<2 cm confirmed by pathological reading, or mucinous cystic tumor (branch duct like IPMN with nodule wall \> 5 mm unresectable) or mucinous cystadenoma with unresectable wall thickening
• Unresectable patient or high operative risk
• Multidisciplinary Collaborative Meeting confirming the indication for treatment.
• Patients who consented to participate in the study
• American Society Anesthesiology classification 1, 2 or 3
• Patient affiliated to the national social security system (beneficiary or assignee)

You may not qualify if:

• Invasive carcinoma lesions in a patient whose clinical condition allows to consider a surgical pancreatic resection
• Severe coagulopathy (PT \<50%, partial thromboplastin time \> 42 sec), thrombocytopenia (\<75,000 G/L), antiplatelets agent
• Patient under anticoagulant agent (NACO, heparin and warfarin)
• American Society Anesthesiology classification 4
• Patient belonging to a so-called vulnerable patient population (pregnancy, nursing, patient trust, guardianship, private patient freedom, ...)
• Women of childbearing age, including in contraception
• Pace maker
• Inability to obtain informed consent

Sponsors & Collaborators

• Société Française d'Endoscopie Digestive: lead

Study Sites (1)

Barthet

Marseille, 13000, France

Location

Related Publications (1)

• Barthet M, Giovannini M, Lesavre N, Boustiere C, Napoleon B, Koch S, Gasmi M, Vanbiervliet G, Gonzalez JM. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy. 2019 Sep;51(9):836-842. doi: 10.1055/a-0824-7067. Epub 2019 Jan 22.

  PMID: 30669161 DERIVED

MeSH Terms

Conditions

Pancreatic Neoplasms; Endocrine Gland Neoplasms; Neoplasms, Cystic, Mucinous, and Serous

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type

Study Officials

• Marc Barthet, MD, PhD

  Assistance Publique des hôpitaux de Marseille

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, MSc

Study Record Dates

• First Submitted: December 20, 2014
• First Posted: January 5, 2015
• Study Start: February 1, 2015
• Primary Completion: February 1, 2017
• Study Completion: February 1, 2017
• Last Updated: June 12, 2018

Record last verified: 2018-06

Locations

FR (1)